DBV Technologies Reports First Quarter 2026 Financial Results
Rhea-AI Summary
DBV Technologies (NASDAQ:DBVT) reported Q1 2026 results with $229M cash as of March 31, 2026, funding operations into Q2 2027 after full exercise of PIPE warrants.
Q1 results show net loss $47.6M and increased R&D and SG&A spending as the company advances BLA submissions for VIASKIN® Peanut Patch and commercial readiness in the U.S.
Positive
- $229M cash and cash equivalents as of March 31, 2026
- Funding runway into Q2 2027 after warrant exercises
- BLA submission planned for children 4–7 in H1 2026
- Initiation planned for Phase 2 THRIVE infant study
Negative
- Net loss widened to $47.6M in Q1 2026
- R&D expenses increased by $12M YoY in Q1
- SG&A increased by $9M YoY in Q1
- Net cash used in operations of $49M in Q1 2026
Key Figures
Market Reality Check
Peers on Argus
DBVT fell 2.4% while only one scanned peer (CAPR) showed upside momentum (+1.97%) and others were mixed, pointing to a stock-specific reaction rather than a broad biotech move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Full-year 2025 results | Positive | -1.0% | Full-year 2025 update with positive Phase 3 data and extended cash runway. |
| Oct 28 | Q3 2025 results | Negative | -2.2% | Q3 2025 results highlighting large losses and going concern uncertainties. |
| Jul 29 | Q2/H1 2025 results | Negative | -4.1% | H1 2025 results with higher expenses, wider net loss, and going concern doubts. |
| Apr 30 | Q1 2025 results | Neutral | -4.4% | Q1 2025 update showing low cash but sizeable new financing commitment. |
| Nov 06 | Q3 2024 results | Negative | -4.0% | Q3 2024 results with high losses, rising expenses, and going concern warnings. |
Earnings-related releases have generally been followed by negative price reactions, with most reports seeing shares trade lower the next day.
Over the past few earnings cycles, DBV Technologies has repeatedly highlighted growing investment in VIASKIN® Peanut development and financing actions to extend runway. Prior updates noted cash of $46.4M in Q3 2024, rising to $13.0M, then $69.8M, and ultimately $194.2M plus additional funding by year-end 2025. Despite positive clinical milestones and strengthened liquidity, earnings-day moves have typically been negative (average around -3%), suggesting investors have focused on losses and spending.
Historical Comparison
In the last five earnings releases, DBVT’s average next-day move was about -3.16%, with most reports trading lower despite improving cash and advancing VIASKIN® Peanut.
Earnings updates trace a shift from tight liquidity and going concern warnings toward progressively larger cash balances and extended runway as VIASKIN® Peanut advances.
Market Pulse Summary
This announcement underscores DBV Technologies’ transition into a pre-commercial phase, with Q1 2026 net loss of $47.6M driven by higher R&D, sales, and G&A as it prepares for potential U.S. launch of the VIASKIN® Peanut Patch. Cash and equivalents rose to $229M, supporting runway into Q2 2027. Recent earnings history shows repeated focus on liquidity and spending, so future updates on BLA filings, commercialization timelines, and operating cash burn will be important markers for investors tracking execution.
Key Terms
biologics license application (bla) regulatory
phase 2 medical
phase 3 medical
open-label extension (ole) medical
u.s. gaap financial
pipe financing financial
pre-commercial inventory technical
research tax credit financial
AI-generated analysis. Not financial advice.
Châtillon, France, April 30, 2026
DBV Technologies Reports First Quarter 2026 Financial Results
- Reported cash and cash equivalents of
$229 million as of March 31, 2026 —providing funding into the second quarter of 2027 following the full exercise of the ABSA Warrants and BS Warrants issued in its March 2025 private placement (“PIPE”) financing - Continued disciplined execution focused on BLA filing in the first half of this year and commercial preparedness for the U.S. launch of the VIASKIN® Peanut Patch for children aged 4 to 7 years, if approved
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today reported financial results for the first quarter of 2026. The quarterly and three months unaudited condensed financial statements were approved by the Board of Directors on April 30, 2026.
“The entire DBV team has been operating with exceptional focus and rigor as we progress towards significant milestones in the coming months, including the upcoming Biologics License Application (BLA) submissions for both our Children ages 4-7 and Toddler ages 1-3 programs in first half and second half of this year, respectively.” said Daniel Tassé, Chief Executive Officer of DBV Technologies. “We also plan to initiate a first of its kind study in infants ages 6 through 12 months. This Phase 2 study, previously announced at last year's American College of Asthma, Allergy, and Immunology, and now called THRIVE, will assess the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in peanut-allergic infants 6 through 12 months of age following a minimum of 3 years of treatment. Across all development programs, we are operating with extreme precision and purpose with the goal of providing practical, non-invasive treatment options to peanut allergy families no matter where they are on their treatment journey.”
Financial Highlights for the First Quarter Ended March 31, 2026
The Company’s interim unaudited condensed consolidated financial statements for the three months ended March 31, 2026, and the comparative period of March 31, 2025, are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
In the first quarter of 2026, the Company started to execute its plan for growth, building on the key events from 2025, including the receipt of regulatory alignment with the U.S. Food and Drug Administration in the first quarter of 2025 regarding the safety data requirements and positive phase 3 clinical results in the fourth quarter, that will both support the planned BLA submission for the VIASKIN® Peanut Patch in children aged 4 to 7 years in the first half of 2026.
Financial Performance
Operating Income
For the three months ended March 31, 2026, the Company accrued
Research and Development Expenses
R&D expenses increased by
- Clinical-related expenses driven by the ongoing recruitment for the COMFORT Toddlers study, the VITESSE Open-label extension (OLE), and the acceleration of BLA-readiness activities.
- Investment in Medical Affairs, Quality and Regulatory functions in the United States.
- Continuous Pre-Commercial Inventory build-up in preparation for the launch of the VIASKIN® Peanut Patch for children aged 4 to 7 years in the U.S., if approved.
Selling, General and Administrative (“SG&A”) Expenses
SG&A Expenses increased by
Net Loss
Net loss was
Cash Position and Liquidity
On March 31, 2026, the Company held
Based on current operations, plans, and assumptions, management has determined that its Cash and Cash Equivalents are sufficient to fund its operations into the second quarter of 2027.
These estimates are based on the Company’s current forecasts and exclude any additional expenditures related to programs other than the VIASKIN Peanut or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based these estimates on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated.
Unaudited condensed Consolidated Statement of Operations
| (In millions of USD) | US GAAP Three months ended March 31 | |
| 2026 | 2025 | |
| Operating income | 0.9 | 0.8 |
| Operating expenses | ||
| Research and development expenses | (33.4) | (21.5) |
| Sales and marketing expenses | (4.8) | (0.3) |
| General and administrative expenses | (10.5) | (5.6) |
| Total Operating expenses | (48.8) | (27.4) |
| Loss from operations | (47.9) | (26.6) |
| Financial income (expense) | 0.5 | (0.5) |
| Loss before taxes | (47.4) | (27.1) |
| Income tax | (0.2) | - |
| Net loss | (47.6) | (27.1) |
| Basic/diluted Net loss per share attributable to shareholders* | (0.11) | (0.26) |
* Following the March 2025 PIPE financing, this weighted-average share count includes the shares underlying the pre-funded warrants, as the remaining cash exercise price for those warrants is considered immaterial.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of the VIASKIN Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding the Company’s financial condition, forecast of its cash runway, the therapeutic potential of Viaskin® patch, designs of DBV’s anticipated clinical trials, including the planned Phase 2 THRIVE study in peanut-allergic infants aged 6 through 12 months, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, clinical trial data releases and publications, the potential regulatory submissions, regulatory approval, launch and commercialization of the Company’s product candidates, the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies, and the Company’s business strategy and goals. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the Company’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the Company’s ability to successfully execute on its growth plans, commercial readiness activities and BLA-related efforts, risks related to the commercialization and launch of the Company’s product candidates, including market acceptance, pricing and reimbursement, and the Company’s ability to obtain additional financing on acceptable terms, if needed, to fund its operations. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, as amended by the Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026, and future filings and reports made with the SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
Jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
Brett.whelan@dbv-technologies.com
Attachment
